vs
WARRIOR MET COAL, INC.（HCC）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是WARRIOR MET COAL, INC.的1.6倍（$622.0M vs $384.0M），Royalty Pharma plc净利率更高（34.4% vs 6.0%，领先28.5%），WARRIOR MET COAL, INC.同比增速更快（29.1% vs 4.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -12.7%）
Warrior Met Coal（股票代码HCC）是总部位于美国的矿业企业，主营高品质冶金煤的开采与供应，其产品是钢铁制造的核心原材料，主要服务北美、欧洲、亚洲地区的钢铁生产商及工业客户。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
HCC vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.6倍
$384.0M
营收增速更快
HCC
高出24.3%
4.8%
净利率更高
RPRX
高出28.5%
6.0%
两年增速更快
RPRX
近两年复合增速
-12.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $384.0M | $622.0M |
| 净利润 | $23.0M | $214.2M |
| 毛利率 | 29.5% | — |
| 营业利润率 | 9.0% | 62.4% |
| 净利率 | 6.0% | 34.4% |
| 营收同比 | 29.1% | 4.8% |
| 净利润同比 | 1919.5% | 2.9% |
| 每股收益（稀释后） | $0.43 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HCCRPRX
| Q4 25 | $384.0M | $622.0M | ||
| Q3 25 | $328.6M | $609.3M | ||
| Q2 25 | $297.5M | $578.7M | ||
| Q1 25 | $299.9M | $568.2M | ||
| Q4 24 | $297.5M | $593.6M | ||
| Q3 24 | $327.7M | $564.7M | ||
| Q2 24 | $396.5M | $537.3M | ||
| Q1 24 | $503.5M | $568.0M |
净利润HCCRPRX
| Q4 25 | $23.0M | $214.2M | ||
| Q3 25 | $36.6M | $288.2M | ||
| Q2 25 | $5.6M | $30.2M | ||
| Q1 25 | $-8.2M | $238.3M | ||
| Q4 24 | $1.1M | $208.2M | ||
| Q3 24 | $41.8M | $544.0M | ||
| Q2 24 | $70.7M | $102.0M | ||
| Q1 24 | $137.0M | $4.8M |
毛利率HCCRPRX
| Q4 25 | 29.5% | — | ||
| Q3 25 | 27.1% | — | ||
| Q2 25 | 23.9% | — | ||
| Q1 25 | 18.1% | — | ||
| Q4 24 | 23.1% | — | ||
| Q3 24 | 29.3% | — | ||
| Q2 24 | 34.1% | — | ||
| Q1 24 | 43.3% | — |
营业利润率HCCRPRX
| Q4 25 | 9.0% | 62.4% | ||
| Q3 25 | 6.3% | 70.1% | ||
| Q2 25 | 2.6% | 36.3% | ||
| Q1 25 | -5.8% | 94.0% | ||
| Q4 24 | -1.4% | 60.9% | ||
| Q3 24 | 11.9% | — | ||
| Q2 24 | 17.9% | 50.2% | ||
| Q1 24 | 29.6% | -13.0% |
净利率HCCRPRX
| Q4 25 | 6.0% | 34.4% | ||
| Q3 25 | 11.1% | 47.3% | ||
| Q2 25 | 1.9% | 5.2% | ||
| Q1 25 | -2.7% | 41.9% | ||
| Q4 24 | 0.4% | 35.1% | ||
| Q3 24 | 12.7% | 96.3% | ||
| Q2 24 | 17.8% | 19.0% | ||
| Q1 24 | 27.2% | 0.8% |
每股收益（稀释后）HCCRPRX
| Q4 25 | $0.43 | $0.49 | ||
| Q3 25 | $0.70 | $0.67 | ||
| Q2 25 | $0.11 | $0.07 | ||
| Q1 25 | $-0.16 | $0.55 | ||
| Q4 24 | $0.02 | $0.46 | ||
| Q3 24 | $0.80 | $1.21 | ||
| Q2 24 | $1.35 | $0.23 | ||
| Q1 24 | $2.62 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $300.0M | $618.7M |
| 总债务越低越好 | $154.3M | $9.0B |
| 股东权益账面价值 | $2.1B | $9.7B |
| 总资产 | $2.8B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.07× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资HCCRPRX
| Q4 25 | $300.0M | $618.7M | ||
| Q3 25 | $336.3M | $938.9M | ||
| Q2 25 | $383.3M | $631.9M | ||
| Q1 25 | $454.9M | $1.1B | ||
| Q4 24 | $491.5M | $929.0M | ||
| Q3 24 | $583.2M | $950.1M | ||
| Q2 24 | $709.0M | $1.8B | ||
| Q1 24 | $693.9M | $843.0M |
总债务HCCRPRX
| Q4 25 | $154.3M | $9.0B | ||
| Q3 25 | $154.1M | $8.9B | ||
| Q2 25 | $153.9M | $8.0B | ||
| Q1 25 | $153.8M | $7.6B | ||
| Q4 24 | $153.6M | $7.6B | ||
| Q3 24 | $153.5M | $7.6B | ||
| Q2 24 | $153.3M | $7.6B | ||
| Q1 24 | $153.2M | $6.1B |
股东权益HCCRPRX
| Q4 25 | $2.1B | $9.7B | ||
| Q3 25 | $2.1B | $9.6B | ||
| Q2 25 | $2.1B | $9.5B | ||
| Q1 25 | $2.1B | $9.8B | ||
| Q4 24 | $2.1B | $10.3B | ||
| Q3 24 | $2.1B | $10.3B | ||
| Q2 24 | $2.0B | $9.8B | ||
| Q1 24 | $2.0B | $9.9B |
总资产HCCRPRX
| Q4 25 | $2.8B | $19.6B | ||
| Q3 25 | $2.7B | $19.3B | ||
| Q2 25 | $2.6B | $18.3B | ||
| Q1 25 | $2.6B | $17.6B | ||
| Q4 24 | $2.6B | $18.2B | ||
| Q3 24 | $2.6B | $18.0B | ||
| Q2 24 | $2.6B | $17.7B | ||
| Q1 24 | $2.5B | $16.1B |
负债/权益比HCCRPRX
| Q4 25 | 0.07× | 0.92× | ||
| Q3 25 | 0.07× | 0.93× | ||
| Q2 25 | 0.07× | 0.84× | ||
| Q1 25 | 0.07× | 0.78× | ||
| Q4 24 | 0.07× | 0.74× | ||
| Q3 24 | 0.07× | 0.74× | ||
| Q2 24 | 0.07× | 0.78× | ||
| Q1 24 | 0.08× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $76.1M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 3.31× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流HCCRPRX
| Q4 25 | $76.1M | $827.1M | ||
| Q3 25 | $104.7M | $702.6M | ||
| Q2 25 | $37.5M | $364.0M | ||
| Q1 25 | $10.9M | $596.1M | ||
| Q4 24 | $54.2M | $742.5M | ||
| Q3 24 | $62.2M | $703.6M | ||
| Q2 24 | $147.0M | $658.2M | ||
| Q1 24 | $104.1M | $664.6M |
现金转化率HCCRPRX
| Q4 25 | 3.31× | 3.86× | ||
| Q3 25 | 2.86× | 2.44× | ||
| Q2 25 | 6.70× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | 47.68× | 3.57× | ||
| Q3 24 | 1.49× | 1.29× | ||
| Q2 24 | 2.08× | 6.45× | ||
| Q1 24 | 0.76× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HCC
| Mining Segment | $373.6M | 97% |
| Other | $10.4M | 3% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
